Clinical Trials
45 trialsNCT07156227 2026-05-13
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT06641791 2026-05-12
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT04944914 2026-04-30
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT02713269 2026-04-17
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04693377 2026-04-15
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT04938609 2026-04-09
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
Providence Health & Services
Phase 2 Active not recruiting
NCT03164460 2026-03-20
Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in Treating Patients With Recurrent Head and Neck Cancer
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT06211335 2026-03-12
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
University of California, Davis
Phase 1 Recruiting
NCT05674396 2026-02-19
3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04862455 2026-01-23
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03546582 2026-01-20
KEYSTROKE
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT03070366 2025-09-02
OMET
Groupe Oncologie Radiotherapie Tete et Cou
Phase 2 Active not recruiting
NCT02474368 2025-07-10
Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03635164 2025-06-27
Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma
University of Colorado, Denver
Phase 1 Completed
NCT03169764 2025-02-24
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT05053737 2025-02-03
Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC
University of Colorado, Denver
Phase 1 Completed
NCT04576091 2024-12-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04220775 2024-11-07
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03892720 2024-08-27
Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer
Jonsson Comprehensive Cancer Center
Phase NA Completed
NCT04498767 2024-08-26
OligoRARE
European Organisation for Research and Treatment of Cancer - EORTC
Phase NA Recruiting
NCT04830267 2024-03-28
The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Chongqing University Cancer Hospital
Phase 2 Recruiting
NCT02703493 2024-03-12
Image-Guided Stereotactic Radiosurgery (SRS) Boost for HPV-Oropharyngeal Cancer
Northwell Health
Phase NA Completed
NCT03511391 2024-01-23
CHEERS
University Hospital, Ghent
Phase 2 Completed
NCT03749460 2023-12-29
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
University of Washington
Phase 1/2 Completed
NCT03618134 2023-11-18
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
Jonsson Comprehensive Cancer Center
Phase 1/2 Terminated
NCT05259319 2023-10-17
IMMUNOs-SBRT
Centre Georges Francois Leclerc
Phase 1 Unknown
NCT04834349 2023-09-13
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03522584 2023-06-12
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Washington
Phase 1/2 Terminated
NCT02057107 2023-06-05
SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN
University of Pittsburgh
Phase 2 Completed
NCT02158234 2023-01-19
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT05431764 2022-06-24
Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT03122496 2022-06-08
Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02684253 2022-03-10
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01104922 2022-02-14
Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
University of Pittsburgh
Phase 2 Completed
NCT02516969 2022-01-14
Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
University of Pittsburgh
Phase NA Completed
NCT03402737 2021-02-18
SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&N
University Hospital, Ghent
Phase NA Terminated
NCT04435938 2020-12-02
SHINE
McMaster University
Phase 2 Unknown
NCT04399785 2020-05-22
Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC
West China Hospital
Phase 2 Unknown
NCT01344356 2020-04-10
Stereotactic Body Radiotherapy for Head and Neck Tumors
Mercy Research
Phase 4 Completed
NCT02110992 2019-11-25
Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
University of Cincinnati
Phase 1 Terminated
NCT02388932 2019-01-24
Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer
Case Comprehensive Cancer Center
Phase NA Terminated
NCT00851253 2018-01-17
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
Boston Medical Center
Phase NA Completed
NCT00891904 2016-04-14
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer
Roswell Park Cancer Institute
Phase NA Terminated
NCT01586182 2015-09-04
Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma
Dana-Farber Cancer Institute
Phase 1/2 Withdrawn
NCT00738868 2011-05-13
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed